Fig. 3.

Effects of A1254 exposure on GFAP immunoreactivity in dbcAMP differentiating C6 cells. C6 cells were subjected to different treatments, fixed and then immunocytochemistry was performed as detailed in Section 2.4. C6 cells were cultured in DMEM with 10% FBS (A–C) or kept in serum-free DMEM in presence (G–I) or absence (D–F) of 0.1% (v/v) DMSO (vehicle). Cells exposed to: 3 μM A1254 (J–L); 9 μM A1254 (M–O); 1 mM dbcAMP (P–R). dbcAMP-differentiating cells exposed to A1254 3 μM (S–U) or 9 μM (V–X). After the treatments, cells were subjected to GFAP immunostaining (green) (A, D, G, J, M, P, S and V). DAPI-nuclear stain (blue) of the same field (B, E, H, K, N, Q, T and W). Merge for composite images (C, F, I, L, O, R, U and X). All the treatments were performed for 24 h under serum-free conditions in presence of 0.1% (v/v) DMSO used as vehicle for A1254. Scale bar = 50 μm. (For interpretation of color in Fig. 3, the reader is referred to the web version of this article.)